The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Naprienko M.V.

Moskovskaia meditsinskaia akademiia im. I.M. Sechenova

Smekalkina L.V.

Moskovskaia meditsinskaia akademiia im. I.M. Sechenova

Surnova E.A.

Alexander Vein Clinic of Headache and Vegetative Frustratin, Moscow, Russia

Efficacy of different doses of botox in treatment of chronic migraine

Authors:

Naprienko M.V., Smekalkina L.V., Surnova E.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(8): 44‑48

DOI: 10.17116/jnevro20171178144-48

Read: 7429 times

Download PDF (RU)
Contact the author
Table of contents

EFFICACY OF DIFFERENT DOSES OF BOTOX IN TREATMENT OF CHRONIC MIGRAINE
EFFICACY OF DIFFERENT DOSES OF BOTOX IN TREATMENT OF CHRONIC MIGRAINE

To cite this article:

Naprienko MV, Smekalkina LV, Surnova EA. Efficacy of different doses of botox in treatment of chronic migraine. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(8):44‑48. (In Russ.)
https://doi.org/10.17116/jnevro20171178144-48

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Sequential use of botu­linum toxin A and bovhyaluronidase azoximer in the correction of post-stroke spasticity. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):80-85
Comparative analysis of the effe­ctiveness of Botu­linum toxin type A — hema­gglutinin preparations of the Rela­tox and Botox complex in the treatment of patients with primary idiopathic blepharospasm. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):86-90
Improvement of spinal sensorimotor adaptation in children with cere­bral palsy with various loco­motor patterns using botu­linum therapy and compression orthoses. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):127-135
Evaluation of the effi­cacy and safety of botu­linum toxin type A inje­ctions for the prevention of aspi­ration complications in patients with neurogenic dysphagia and posterior sialorrhea of various etiologies. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(12):126-133
Prevention of pathological skin scars (experimental study). Plastic Surgery and Aesthetic Medi­cine. 2025;(1):32-38
Complexity index of microsurgical treatment of unru­ptured cere­bral aneurysms. Burdenko's Journal of Neurosurgery. 2025;(3):28-41
Prophylactic treatment of migraine in real clinical practice. Russian Journal of Pain. 2025;(2):63-69
Complexity index of endo­vascular treatment of unru­ptured cere­bral aneurysms. Burdenko's Journal of Neurosurgery. 2025;(4):39-50
Vascular endo­thelial growth factor in episodic and chro­nic migraine: new approaches to unde­rstanding pathogenesis. Russian Journal of Pain. 2025;(3):17-21
Botu­linum toxin type A inje­ction in the middle and lower thirds of the face and neck area for aesthetic purposes. Plastic Surgery and Aesthetic Medi­cine. 2025;(3):108-117
Abstract:

Objective. To compare the efficacy of botox used in doses of 155 U and 195 U for preventive treatment of chronic migraine (CM). Material and methods. Thirty-nine women with CM were stratified into two groups according to the dose of botox. The duration of the study was 9 month, patient’s state was assessed before treatment and after repeated injections (every 3 month). Results and Conclusion. With regard to the frequency of migraine attacks, the 1st and 2nd injections of botox were equally effective. After the 3rd injection, the frequency was significantly lower in group 2 (195 U). After 2nd and 3rd injections, an effect on patient’s adaptation assessed with the MIDAS and patient’s satisfaction with treatment were higher. The results suggest the dose-dependent efficacy of repeated injections of botox. The dose of 195 U can be recommended in preventive treatment of CM as more effective.

Keywords:

chronic migraine
preventive treatment
botulinum toxin type A
botox

Authors:

Naprienko M.V.

Moskovskaia meditsinskaia akademiia im. I.M. Sechenova

Smekalkina L.V.

Moskovskaia meditsinskaia akademiia im. I.M. Sechenova

Surnova E.A.

Alexander Vein Clinic of Headache and Vegetative Frustratin, Moscow, Russia

Close metadata

References:

  1. Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, Lipton RB. Global prevalence of chronic migraine: а systematic review. Cephalalgia. 2010;30:599-609. https://doi.org/10.1111/j.1468-2982.2009.01941.x
  2. Ayzenberg I, Katsarava Z, Sborowski A, Chernysh M, Osipova V, Tabeeva G, Yakhno N, Steiner TJ. The prevalence of primary headache disorders in Russia: A countrywide survey. Cephalalgia. 2012;32:373-381. https://doi.org/10.1177/0333102412438977
  3. Naprienko MV, Smekalkina LV. Strategies on the improvement of chronic migraine treatment efficacy. Zhurnal nevrologii I psikhiatrii im. S.S. Korsakova. 2015;12:70-73. (In Russ.). https://doi.org/10.17116/jnevro201511511270-73
  4. Zwart JA, Bovim G, Sand T, Sjaastad O. Tension headache: botulinum toxin paralysis of temporal muscles. Headache. 1994;34:458-462. https://doi.org/10.1111/j.1526-4610.1994.hed3408458.x
  5. Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM. Botulinum toxin type A (BOTOX) for treatment of migraine headache: an open-label study. Otolaryngol Head Neck Surg. 2000;123(6):669-676. https://doi.org/10.1067/mhn.2000.110960
  6. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. Headache. 2000;40:445-450.
  7. Orlova OR, Yakhno N. The use of Botox (botulinum toxin type A) in clinical practice. M.: Katalog; 2001. (In Russ.).
  8. Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache. 2005;45(4):315-324. https://doi.org/10.1111/j.1526-4610.2005.05068.x
  9. Naprienko MV, Oknin VU, Sazonova AG, Kudaeva LM. Type A botulinum toxin (dуsport) in treatment of chronic forms of primary headache. Byulleten` suburskoi meditsiny. 2008;5:270-275. (In Russ.).
  10. Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C; BOTOX CDH Study Group. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache. 2005;45(4):293-307. https://doi.org/10.1111/j.1526-4610.2005.05066.x
  11. Silberstein SD, Stark SR, Lucas SM, Christie SN, DeGryse RE, Turkel CC. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2005;80(9):1126-1137.
  12. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF. PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50:921-936. https://doi.org/10.1111/j.1526-4610.2010.01678.x
  13. Dodick D, Silberstein S. Central sensitization theory of migraine: clinical implications. Headache. 2006;46:182-191. https://doi.org/10.1111/j.1526-4610.2006.00602.x
  14. Aoki KR, Francis J. Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. Parkinsonism Relat Disord. 2011;17(suppl 1):28-33. https://doi.org/10.1016/j.parkreldis.2011.06.013
  15. Kosaras B, Jakubowski M, Kainz V, Burstein R. Sensory innervation of the calvarial bones of the mouse. J Comp Neurol. 2009;515:331-348. https://doi.org/10.1002/cne.22049
  16. Ramachandran R, Yaksh LT. Therapeutic use of botulinum toxin in migraine: mechanisms of action. Br J Pharmacol. 2014;171(18):4177-4192. https://doi.org/10.1111/bph.12763
  17. Burstein R, Zhang X, Levy D, Aoki KR, Brin MF. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. Cephalalgia. 2014;34:853-869. https://doi.org/10.1177/0333102414527648
  18. Goadsby PJ, Lipton RB, Ferrari MD. Migraine: Current understanding and treatment. N Engl J Med. 2002;346:257-270. https://doi.org/10.1056/NEJMra010917
  19. Ozcan C, Vayisoglu Y, Doğu O, Görür K. The effect of intranasal injection of botulinum toxin A on the symptoms of vasomotor rhinitis. Am J Otolaryngol. 2006;27(5):314-318. https://doi.org/10.1016/j.amjoto.2006.01.008
  20. Headache Classification Committee of the International Headache Society (IHS); The International Classification of Headache Disorders: 3rd Edition. Celphalalgia. 2013;33(9):629-808. https://doi.org/10.1177/0333102413485658
  21. Abbasoglu OE, Sener EC, Sanac AS. Factors influencing success and dose-effect relation of botulinum A treatment. Eye (Lond). 1996;10(Pt 3):385-391. https://doi.org/10.1038/eye.1996.78
  22. Stone AV, Ma J, Callahan MF, Smith BP, Garrett JP, Smith TL, Koman LA. Dose- and Volume Dependent-Response to Intramuscular Injection of Botulinum Neurotoxin-A Optimizes Muscle Force Decrement in Mice. J Orthop Res. 2011;29(11):1764-1770. https://doi.org/10.1002/jor.21434
  23. Aurora SK, Dodick DW, Diener HC, Degryse RE, Turkel CC, Lipton RB, Silberstein SD. Onabotulinumtoxin A for chronic migraine: efficacy, safety and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. Acta Neurol Scand. 2014;129:61-70. https://doi.org/10.1111/ane.12171
  24. Silberstein SD, Dodick WD, Aurora SK, Dienere H-C, DeGryse RE, Lipton RB, Turkel CC. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. J Neurol Neurosurg Psychiatry. 2015;86:996-1001. https://doi.org/10.1136/jnnp-2013-307149
  25. Finzi E, Wasserman E. Treatment of depression with botulinum toxin A: a case series. Dermatol Surg. 2006;32(5):645-650. https://doi.org/10.1111/j.1524-4725.2006.32136.x
  26. Hepp Z, Bloudek LM, Varon SF. Adherence to oral migraine-preventive medications among patients with chronic migraine. J Manag Care Pharm. 2014;20:22-33. https://doi.org/10.1177/0333102414547138
  27. Linde M, Jonsson P, Hedenrud T. Influence of disease features on adherence to prophylactic migraine medication. Acta Neurol Scand. 2008;118(6):367-372. https://doi.org/10.1111/j.1600-0404.2008.01042.x
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.